MDCT vs. CBCT Guided Percutaneous Lung Nodule Biopsy: A Comparison of Pneumothorax Incidence and Associated Risk Factors
Primary Purpose
Lung Diseases
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
cone beam computed tomography (CBCT) for percutaneous transthoracic needle biopsy
Sponsored by
About this trial
This is an interventional health services research trial for Lung Diseases
Eligibility Criteria
Inclusion Criteria:
- Patients scheduled for lung biopsy at Mather Hospital's Department of Interventional Radiology.
- Patients ages from 18 years old to 90 years old.
Exclusion Criteria:
- High risk patients will be excluded from the study.
- ( High risk - Any patient with severe emphysema with bullous emphysema on baseline Computed Tomography of the Chest, intended biopsy target/nodule adjacent to an airway or central vasculature, or less than 1 cm in size)
- Patients less than 18 years old
- Patients older than 90 years old
- patients who lack mental capacity for medical decision making
- Any patient requiring or requesting general anesthesia for the intended procedure
Sites / Locations
- Mather Hospital Northwell HealthRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Other
Other
Arm Label
cone beam computed tomography (CBCT) for percutaneous transthoracic needle biopsy
multidetector computed tomography (MDCT) for percutaneous transthoracic needle biopsy
Arm Description
Cone beam Computed Tomography (CBCT) with Navigational software guidance for percutaneous transthoracic needle biopsy
Multidetector Computer Tomography for percutaneous transthoracic needle biopsy
Outcomes
Primary Outcome Measures
To determine the incidence of pneumothorax as a complication of CBCT and CT-guided percutaneous lung biopsy
rate of pneumothorax
Secondary Outcome Measures
To compare the difference in procedure times between biopsy imaging guidance modality
Procedure time ( in minutes)
To compare the amount of intravenous midazolam used between biopsy imaging guidance modality
Amount of Intravenous Midazolam ( in milligrams)
To compare the the amount of intravenous fentanyl used between biopsy imaging guidance modality
Amount of intravenous Fentanyl ( in micrograms)
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05344430
Brief Title
MDCT vs. CBCT Guided Percutaneous Lung Nodule Biopsy: A Comparison of Pneumothorax Incidence and Associated Risk Factors
Official Title
CT Guided and Cone Beam CT Guided Percutaneous Transthoracic Needle Biopsy: A Comparison of Pneumothorax Incidence and Associated Risk Factors
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 8, 2021 (Actual)
Primary Completion Date
July 8, 2024 (Anticipated)
Study Completion Date
July 8, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Northwell Health
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The goal of this study is to determine if cone beam computed tomography (CBCT) is a viable alternative imaging guidance modality for percutaneous transthoracic needle biopsy (PTNB) in a community hospital-based practice, and to determine the incidence of CBCT PTNB-associated pneumothorax compared to multidetector computed tomography (MDCT) guided PTNB biopsy. The standard of care in this facility is MDCT guided PTNB biopsy. The experimental arm of this study is CBCT-guided PTNB biopsy.
This prospective study will identify patients planned for PTNB. Thereafter, data on lesion characteristics, imaging findings, and clinical history will be collected. Patients will be subsequently randomly assigned to undergo biopsy using either CBCT or MDCT guidance. This study will analyze the pneumothorax incidence between groups, and assess for associations between lesion size/location, pertinent imaging findings, and clinical risk factors.
Detailed Description
Studies have shown that CBCT is a viable imaging modality for PTNB. Although MDCT-guidance remains the preferred procedural modality, research has shown that CBCT-guided biopsies can be carried out safely and effectively. Particularly, studies demonstrate a satisfactory diagnostic yield, low complication rate, and overall reduced patient radiation dose. However, only a handful of studies have compared this method to MDCT-guided biopsy.
In this 248-bed community hospital-based interventional radiology practice, C-Arm CBCT was successfully utilized during a three-month period when a dedicated procedural CT scanner was out of service prior to the installation of a new machine. During this time, CBCT was used to perform PTNB. This study was prompted given the operators' perception that there was an overall increased incidence of biopsy-associated pneumothoraxes. Given this subjective experience, a retrospective analysis was carried out comparing the complication rate during these three months to the preceding six-month period, when MDCT-guidance was primarily used.
For the primary analysis, patients were grouped based on imaging modality (CBCT n=37; CT n=64). Multiple Pearson Chi-Square Tests were carried out using p=.05 as the statistical threshold. Additional analyses dividing patient based on lesion size (≥/< 2 cm in diameter), lesion pleural depth (≥/< 2 cm pleural depth), bullous lung change on imaging, chest tube placement, history of COPD, and smoking history were also carried out to assess for related pneumothorax risk factors.
The investigators found no significant association between the imaging modality used for PTNB and subsequent pneumothorax (p=.69). However, there was a significant interaction between chest tube placement and diagnosed chronic obstructive pulmonary disease (COPD) (p=.03), where among all study subjects, 6 of the 8 patients requiring a chest tube had a history of chronic obstructive pulmonary disease (COPD). Additionally, all patients requiring chest tube placement were either current or former smokers. This finding approached but did not reach statistical significance (p=0.12).
This study did not confirm the perceived increased pneumothorax rate. However, the findings corroborate previously published literature, where complication rates between CBCT and MDCT-guidance are reportedly comparable. This experience demonstrates that CBCT can be successfully utilized in a community hospital setting, where limited resources often prompt the need for alternative and innovative procedural approaches.
Outcomes:
To determine the incidence of pneumothorax as a complication of CBCT and CT-guided percutaneous lung biopsy.
To determine if there is an association between biopsy imaging guidance modality, lesion characteristics, and associated clinical risk factors.
To collect data that may be used in the future for biopsy modality risk stratification. This is significant, since resource allocation in community hospital settings may be necessary more frequently, compared to larger hospital settings. Therefore, proper risk stratification is needed for appropriate delivery of high quality and safe patient care.
Methods:
The Interventional Radiology department at Mather Hospital has a robust referral volume from the community oncologists and pulmonologist. In the past year, over 150 CT-guided PTNBs of the lung were performed.
The number of patients that can be recruited for this study is essentially unlimited. The only limiting factor would be the number of lung biopsies scheduled in the study institution per year.
Research protocols will be distributed to the scheduling staff to make them aware of the randomization process, to enable appropriate scheduling of research participants to the correct imaging modality and procedure room.
Outpatients scheduled for lung biopsy will be identified by the departmental interventional radiologists.
This study is exploratory in nature. As a result, the investigators are estimating that 50 patients per treatment arm is sufficient to detect a moderate effect size difference between groups.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lung Diseases
7. Study Design
Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
100 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
cone beam computed tomography (CBCT) for percutaneous transthoracic needle biopsy
Arm Type
Other
Arm Description
Cone beam Computed Tomography (CBCT) with Navigational software guidance for percutaneous transthoracic needle biopsy
Arm Title
multidetector computed tomography (MDCT) for percutaneous transthoracic needle biopsy
Arm Type
Other
Arm Description
Multidetector Computer Tomography for percutaneous transthoracic needle biopsy
Intervention Type
Procedure
Intervention Name(s)
cone beam computed tomography (CBCT) for percutaneous transthoracic needle biopsy
Intervention Description
We will be conducting cone beam computer tomography for percutaneous transthoracic needle biopsies.
Primary Outcome Measure Information:
Title
To determine the incidence of pneumothorax as a complication of CBCT and CT-guided percutaneous lung biopsy
Description
rate of pneumothorax
Time Frame
Up to 24 hours post biopsy procedure
Secondary Outcome Measure Information:
Title
To compare the difference in procedure times between biopsy imaging guidance modality
Description
Procedure time ( in minutes)
Time Frame
immediately after the biopsy procedure
Title
To compare the amount of intravenous midazolam used between biopsy imaging guidance modality
Description
Amount of Intravenous Midazolam ( in milligrams)
Time Frame
immediately after the biopsy procedure
Title
To compare the the amount of intravenous fentanyl used between biopsy imaging guidance modality
Description
Amount of intravenous Fentanyl ( in micrograms)
Time Frame
immediately after the biopsy procedure
10. Eligibility
Sex
All
Gender Based
Yes
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients scheduled for lung biopsy at Mather Hospital's Department of Interventional Radiology.
Patients ages from 18 years old to 90 years old.
Exclusion Criteria:
High risk patients will be excluded from the study.
( High risk - Any patient with severe emphysema with bullous emphysema on baseline Computed Tomography of the Chest, intended biopsy target/nodule adjacent to an airway or central vasculature, or less than 1 cm in size)
Patients less than 18 years old
Patients older than 90 years old
patients who lack mental capacity for medical decision making
Any patient requiring or requesting general anesthesia for the intended procedure
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Kenny Lien, MD
Phone
631-473-1320
Email
klien@northwell.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Greg Haggerty, PhD
Phone
516-551-8655
Email
ghaggerty@northwell.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kenny Lien, MD
Organizational Affiliation
Interventional Radiologist
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mather Hospital Northwell Health
City
Port Jefferson
State/Province
New York
ZIP/Postal Code
11777
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kenny Lien, MD
Phone
631-473-1320
Email
klien@northwell.edu
First Name & Middle Initial & Last Name & Degree
Greg Haggerty, PhD
Phone
516-551-8655
Email
ghaggerty@northwell.edu
First Name & Middle Initial & Last Name & Degree
Kenny Lien, MD
First Name & Middle Initial & Last Name & Degree
Giovanni Santoro, MD
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
MDCT vs. CBCT Guided Percutaneous Lung Nodule Biopsy: A Comparison of Pneumothorax Incidence and Associated Risk Factors
We'll reach out to this number within 24 hrs